Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
News-Medical.Net on MSN
Researchers uncover how HIV-1 uses RNA:DNA hybrids to integrate into the genome
Researchers at the German Center for Infection Research (DZIF) at Heidelberg University Hospital have decoded a previously ...
A groundbreaking discovery reveals how HIV integrates its genetic material into human DNA, exposing a key viral vulnerability ...
Cheap generic versions of a groundbreaking HIV-prevention jab should be available in more than 100 countries from 2027, ...
Scientists say the drug stops the virus from replicating inside cells. The landmark deal to provide cheaper antiretroviral ...
The rollout of antiretroviral therapy for HIV showed how global solidarity and smart policy can overcome barriers to new ...
For over three decades, HIV has played an elaborate game of hide-and-seek with researchers, making treating—and possibly even ...
Hetero and Dr Reddy’s will be funded by the Gates Foundation and Unitaid to produce and sell the twice-a-year anti-HIV shot ...
Rough Draft Atlanta on MSN
AIDS Walk raises $1 million for HIV care
The LGBTQ+ community and its allies gathered for the 34th Annual AIDS Walk Music Festival and 5k Run on Sept. 27, raising $1 ...
Staff with PEERS Alliance and the P.E.I. Trans Network are hosting a lino cutting workshop as part of a broader art project ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback